BOSTON, Aug. 23, 2011 /PRNewswire/ — Solos Endoscopy, Inc.
(OTCPK: SNDY) is pleased to announce that it has consummated
agreements which will result in the reduction of more than $620,000
in debt for the period ending September 30, 2011. The signed
settlement agreement and new consulting agreement will result in a
reduction of ongoing expenses by $60,000 per quarter.
Solos Endoscopy posted its financial statements for period ended
June 30, 2011. While the Company saw a modest decrease in
sales over the period, Management is extremely pleased with the
increase in demand for its new MammoView® instrument line.
The MammoView® instrument line, designed exclusively for
breast endoscopy, has become crucial to early breast cancer
screening as a method to significantly reduce breast cancer death
rates. The Solos MammoView® Breast Endoscopy System is designed
to distinguish and inspect suspicious pre-cancerous lesions that
are undetectable by other methods as well as complement existing
diagnosis and treatment options with direct endoscopic
observation.
“We have allocated significant resources to the development of
the MammoView® instrument line. The fact that we have
taken this tremendous product from concept phase to sales in dozens
of hospitals across the Country is truly amazing. I’d like to
thank the shareholders for all their continued support,” stated Bob
Segersten, President of Solos Endoscopy, Inc.
Please visit http://www.otcmarkets.com/stock/SNDY/financials
for more information.
About Solos Endoscopy, Inc.:
Solos Endoscopy, Inc. is a HealthCare instrument company whose
mission is to develop and market high quality and innovative
instruments for the screening, diagnosis, treatment and management
of medical conditions. Additional information on its FDA approved
products is available on the Company’s web
‘/>”/>
SOURCE
